

**Complete if Known**

Application Number	10/585,928
Filing Date	July 13, 2006
First Named Inventor	ZIV, Ilan
Art Unit	1615
Examiner Name	SAMALA, JAGADISHWAR RAO
Attorney Docket Number	P-8972-US

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	P-8972-US
-------	---	----	---	------------------------	-----------

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
	B	WO 97/00848	Jan. 9, 1997	BNFL Fluorochemicals		<input type="checkbox"/>
	C	JP 57 08538	May 28, 1982	DAIKIN		<input type="checkbox"/>
	D	FR 2 274 600	Jan. 9, 1976	SANDOZ		<input type="checkbox"/>
	E	FR 2 197 873	Mar. 29, 1974	RICHTER, Gedeon		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/585,928
				Filing Date	July 13, 2006
				First named Inventor	ZIV, Ilan
				Art Unit	1615
				Examiner Name	SAMALA, JAGADISHWAR RAO
Sheet	2	of	2	Attorney Docket Number	P-8972-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
F		GERSHON H. Organic fluorine compounds.II., Journal of Medicinal Chemistry, 1967, p. 186-188, vol. 10, no. 2, American Chemical Society	<input type="checkbox"/>
G		BEVERS, E.M., et al., Lipid translocation across the plasma membrane of mammalian cells, Biochimica et Biophysica Acta 1439 (1999) 317-330 Elsevier	<input type="checkbox"/>
H		BOMBELI, T., et al, Apoptotic Vascular Endothelial Cells Become Procoagulant, Blood, April 1, 1997, pp 2429-2442, Vol 89, No 7, American Society of Hematology, Washington DC	<input type="checkbox"/>
I		BRATTIN, D.L., et al, Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and Is Enhanced by Loss of the Aminophospholipid Translocase, The Journal Of Biological Chemistry, October 17, 1997, pp. 26159-26165, Vol. 272, No. 42, The American Society for Biochemistry and Molecular Biology, Inc.	<input type="checkbox"/>
J		BÜRSCH, W., et al, Cell death by apoptosis and its protective role against disease, Trends Pharmacol Sci. 1992 Jun;13(6):245-51.	<input type="checkbox"/>
K		KOCKX M.M., et al, Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res., 2000, 736-746, vo. 45, Elsevier	<input type="checkbox"/>
L		MALLAT, Z., et al, Colocalization of CPP-32 With Apoptotic Cells in Human Atherosclerotic Plaques Circulation, 1997; 424-428 Vol. 96, American Heart Association, Inc.	<input type="checkbox"/>
M		MARTIN, S., et al, Early Redistribution of Plasma Membrane Phosphatidylserine Is a General Feature of Apoptosis Regardless of the Initiating Stimulus: Inhibition by Overexpression of Bcl-2 and Abl, J. Exp.Med., November 1, 1995, 1545 Vol. 182	<input type="checkbox"/>
N		PUGSLEY, W., et al, The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning, Stroke, 1994, 1393-1399, Vol 25, American Heart Association	<input type="checkbox"/>
O		SIMS, P.J., et al, Unraveling the Mysteries of Phospholipid Scrambling Thromb. Haemost, 2001; p. 266-75, Vol. 86, Schattauer GmbH, Stuttgart	<input type="checkbox"/>
P		STARY, H.C., et al., A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis, Circulation, 1995, p. 1355-1374, Vol. 92, American Heart Association, Inc.	<input type="checkbox"/>
Q		VAN DEN EUNDE, S.M., et al, Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis, Cell Death Differentiation, 1997, p. 311-316, Vol. 4, Stockton Press	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.